The French firm’s Clean Room range comprises ready-to-use trypcase soy broth and thioglycollate media, packaged in double wrapped bottles that have undergone ethylene oxide sterilization.
The new packaging format, which is compliant with the requirements of the European, US and Japanese pharmacopoeias, is available in a wide range of colour-coded, screw-top or septum closure containers.
The products have been specifically designed for application in isolator and clean room settings. According to bioMerieux the range “delivers greater quality and dependability of results” than traditionally packaged testing media.
bioMerieux went on to say that because its product eliminates the need for bottle cleaning during microbial analysis operations, it can help pharmaceutical firms reduce manufacturing costs, expedite regulatory submissions and shorten product release times.
In a statement, Alexandre Merieux, corporate vice president of industrial microbiology at the firm, said that the sterility testing was a core goal for the company. He added that: “Bringing innovation to our pharmaceutical customers’ most critical microbiological controls is a strategic focus for bioMerieux.”
The ever present demand for safe pharmaceutical products means that pharmaceutical manufacturers are under pressure to ensure that the drugs they produce are free of contamination to an even greater degree than is expected of the food industry.
bioMerieux has not responded to in-PharmaTechnologist’s questions.
Sales for H1 climb 9%
bioMerieux’s microbiology division generated revenue of €264m ($382min) in the six months ended June 30, up 6.5 per cent on the unit's contribution for the first half of 2007. The firm attributed the improvement to gains made by its Vitek culture media.
In addition, the firm’s industrial operations arm recorded sales of €78m, up some 10 per cent on those achieved last year, driven by the performance of its Vidas and Tempo technologies.
Overall, sales were up 9 per cent to €528m, despite a dip of 0.3 per cent to €109m in revenue derived from North America. bioMerieux’s operations in Asia-Pacific and Latin-America grew 13 per cent and 20 per cent, respectively, with Europe, its most lucrative market generating €327m, up 11 per cent on the first half of last year.